Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2025

Original Article

Semaglutide/Tirzepatide and neurodegeneration and stroke

Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity.

JAMA Network Open

Citation & Authors

JAMA Netw Open. 2025;8(7):e2521016.

Huan-Tang Lin; Yung-Fong Tsai; Pei-Lun Liao; James Cheng-Chung Wei

ABSTRACT · RESEARCH SUMMARY

Research summary

The study matched 30,430 patients per group with type 2 diabetes and obesity to compare semaglutide/tirzepatide with other glucose-lowering drugs. Over up to 7 years, dementia (HR 0.63; 95% CI 0.50–0.81), stroke, and death were less frequent, while Parkinson’s disease and intracerebral hemorrhage did not differ significantly. The findings suggest potential neurovascular benefits that require confirmation in trials.

Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗